Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.

The Lancet. Microbe - 1 Sept 2020

Chappell Catherine A, Scarsi Kimberly K, Kirby Brian J, Suri Vithika, Gaggar Anuj, Bogen Debra L, Macio Ingrid S, Meyn Leslie A, Bunge Katherine E, Krans Elizabeth E, Hillier Sharon L

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiological changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Fluorenes

Share to Hepacivirus

Share to Hepatitis C

Share to Pregnant People

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 32939459
DOI: 10.1016/S2666-5247(20)30062-8
PMCID: PMC7491553

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.PMID 32939459Read ↗

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIVSemantic proximity Read ↗

When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Semantic proximity Read ↗

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion ExperimentsSemantic proximity Read ↗

Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 WomenSemantic proximity Read ↗

Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.Semantic proximity Read ↗

Pregnancy-Related Effects on Tenofovir Pharmacokinetics: a Population Study with 186 WomenSemantic proximity Read ↗

Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Pharmacogenetics of efavirenz exposure in cervicovaginal fluid during pregnancy and postpartumSemantic proximity Read ↗

Call to Action: Harmonisation of Pharmacovigilance Regulations for Post-marketing Pregnancy and Breastfeeding Safety StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.